Evidence map›Paper›PMID 35435126›Full record

ArticleBioengineered2022

Plasmacytoma variant translocation 1 stabilized by EIF4A3 promoted malignant biological behaviors of lung adenocarcinoma by generating circular RNA LMNB2.

Minglian Qiu, Meizhen Chen, Zhongping Lan, Bo Liu, Jinbao Xie, Xu Li

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. RNA-Binding Proteins (RBPs) and Circular RNA Biogenesis.Advances in experimental medicine and biology · 2025
    Review
  4. Formation of Circular RNAs.Advances in experimental medicine and biology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Minglian QiuDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Jiangxi, China.
Meizhen ChenDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Jiangxi, China.
Zhongping LanDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Jiangxi, China.
Bo LiuDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Jiangxi, China.
Jinbao XieDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Jiangxi, China.
Xu LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Jiangxi, China.
Fujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence suggests that plasmacytoma variant translocation 1 (PVT1) plays a vital role in the development of multiple tumors including lung adenocarcinoma (LUAD). Eukaryotic initiation factor 4A-3 (EIF4A3) is considered a key factor in human cancers. However, the role and potential mechanism of PVT1 combined with EIF4A3 in LUAD remain unclear. This study investigated the effects and regulatory mechanisms of PVT1, EIF4A3, and circLMNB2 on the growth, migration, invasion, and epithelial-mesenchymal transition (EMT) of LUAD cells (H1299 and HCC827 cells) The expression level, diagnostic value and prognostic significance of PVT1, EIF4A3, and circLMNB2 were assessed, and enrichment analysis was performed using R package. Rescue experiments and a xenograft model were used to validate the PVT1/EIF4A3/circLMNB2 axis in LUAD. PVT1 and EIF4A3 were upregulated and indicated poor prognosis in LUAD. Knockdown of PVT1 and EIF4A3 suppressed LUAD cell proliferation, migration, invasion, and EMT. Mechanistically, PVT1 was stabilized by EIF4A3. PVT1 could recruit EIF4A3 to promote circLMNB2 expression. Rescue experiments indicated that circLMNB2 overexpression could reverse the reduced behavior caused by PVT1 or EIF4A3 knockdown. Enrichment analysis showed that PVT1/EIF4A3/circLMNB2 may regulate LUAD development by participating in ribosome biogenesis and spliceosome formation. Our findings demonstrate that PVT1/EIF4A3/circLMNB2 enhances the malignant behaviors of LUAD cells, providing a novel perspective for the clinical treatment of LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsCell Line, TumorCell MovementCell ProliferationDEAD-box RNA HelicasesEukaryotic Initiation Factor-3Eukaryotic Initiation Factor-4AGene Expression Regulation, NeoplasticHumansRNA, CircularRNA, Long NoncodingDEAD-box RNA HelicasesEIF4A3 protein, humanEukaryotic Initiation Factor-3Eukaryotic Initiation Factor-4APVT1 long-non-coding RNA, humanRNA, CircularRNA, Long Noncodingcell proliferationcircLMNB2EIF4A3epithelial-mesenchymal transitioninvasionlung adenocarcinomamigrationprognosisPVT1

Identifiers

PMID35435126
PMCPMC9161831
OpenAlexW4224096772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.